{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:58:43Z","timestamp":1776693523083,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K022733\/1"],"award-info":[{"award-number":["MR\/K022733\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wellcome\/EPSRC Centre for Medical Engineering","award":["WT 203148\/Z\/16\/Z"],"award-info":[{"award-number":["WT 203148\/Z\/16\/Z"]}]},{"DOI":"10.13039\/100013376","name":"IoPPN","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013376","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000656","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000656","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.nucmedbio.2018.08.005","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T07:37:31Z","timestamp":1535614651000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Assessing the feasibility of intranasal radiotracer administration for in brain PET imaging"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1312-688X","authenticated-orcid":false,"given":"Nisha","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3562-0683","authenticated-orcid":false,"given":"Mattia","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"O'Doherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Sementa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1309-3045","authenticated-orcid":false,"given":"Salvatore","family":"Bongarzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Cash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Arcolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul K.","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8389-9012","authenticated-orcid":false,"given":"Antony","family":"Gee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico E.","family":"Turkheimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0196-0644(97)70356-1","article-title":"Intranasal midazolam in patients with status epilepticus","volume":"29","author":"Kendall","year":"1997","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.103.063222","article-title":"Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration","volume":"309","author":"Banks","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","article-title":"Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence","volume":"27","author":"Freiherr","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0020","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1023\/B:PHAM.0000026431.55383.69","article-title":"Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study","volume":"21","author":"van den Berg","year":"2004","journal-title":"Pharm Res"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/10611860310001640075","article-title":"Hydroxocobalamin uptake into the cerebrospinal fluid after nasal and intravenous delivery in rats and humans","volume":"11","author":"Van den Berg","year":"2003","journal-title":"J Drug Target"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0030","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1034\/j.1600-0773.2000.pto870606.x","article-title":"Local transfer of diazepam, but not of cocaine, from the nasal cavities to the brain arterial blood in rats","volume":"87","author":"Einer-Jensen","year":"2000","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0035","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1212\/01.WNL.0000067993.60735.77","article-title":"Direct access of drugs to the human brain after intranasal drug administration?","volume":"60","author":"Merkus","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357022539","article-title":"Is nose-to-brain transport of drugs in man a reality?","volume":"56","author":"Illum","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0045","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0050","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0055","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.brainres.2014.01.049","article-title":"Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth","volume":"1580","author":"Anagnostou","year":"2014","journal-title":"Brain Res"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0060","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.psyneuen.2011.07.020","article-title":"Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome","volume":"37","author":"Hall","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0065","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/1871527311312020012","article-title":"The role of intranasal oxytocin in the treatment of patients with schizophrenia: a systematic review","volume":"12","author":"De Berardis","year":"2013","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2011.07.027","article-title":"Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia","volume":"132","author":"Pedersen","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamapsychiatry.2017.3738","article-title":"The promise of intranasal esketamine as a novel and effective antidepressant","volume":"75","author":"Quintana","year":"2018","journal-title":"JAMA Psychiat"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0080","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1471-4159.1977.tb10649.x","article-title":"The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat","volume":"28","author":"Sokoloff","year":"1977","journal-title":"J Neurochem"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s13346-012-0121-z","article-title":"Current understanding of nasal morphology and physiology as a drug delivery target","volume":"3","author":"Suman","year":"2013","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0105","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0110","first-page":"235","article-title":"Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution","volume":"27","author":"Hamacher","year":"1986","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0115","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.nucmedbio.2013.06.003","article-title":"[18F]Fallypride: metabolism studies and quantification of the radiotracer and its radiometabolites in plasma using a simple and rapid solid-phase extraction method","volume":"40","author":"Peyronneau","year":"2013","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0120","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/MNM.0b013e32835674d9","article-title":"Skin contamination of nuclear medicine technologists: incidence, routes, dosimetry and decontamination","volume":"33","author":"Covens","year":"2012","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0125","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1088\/0952-4746\/33\/2\/381","article-title":"Skin dose rate conversion factors after contamination with radiopharmaceuticals: influence of contamination area, epidermal thickness and percutaneous absorption","volume":"33","author":"Covens","year":"2013","journal-title":"J Radiol Prot"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0130","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156720112803529828","article-title":"Anatomical and histological factors affecting intranasal drug and vaccine delivery","volume":"9","author":"Gizurarson","year":"2012","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.rpd.a006705","article-title":"Radionuclide and radiation protection data handbook","volume":"98","author":"Delacroix","year":"2002","journal-title":"Radiat Prot Dosimetry"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10928-005-9001-1","article-title":"Blood-brain barrier penetration of zolmitriptan\u2014modelling of positron emission tomography data","volume":"33","author":"Bergstr\u00f6m","year":"2006","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0145","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1468-2982.2005.00966.x","article-title":"Distribution of intranasal C-zolmitriptan assessed by positron emission tomography","volume":"25","author":"Yates","year":"2005","journal-title":"Cephalalgia"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0150","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0024-3205(97)00149-5","article-title":"The first attempt at radioisotopic evaluation of the integrity of the nose-brain barrier","volume":"60","author":"Okuyama","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","article-title":"Quantitative analysis of drug delivery to the brain via nasal route","volume":"189","author":"Kozlovskaya","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0378-5173(03)00039-5","article-title":"Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats","volume":"255","author":"Dufes","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nucmedbio.2018.08.005_bb0165","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s11095-008-9550-2","article-title":"Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model","volume":"25","author":"Charlton","year":"2008","journal-title":"Pharm Res"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805118302166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805118302166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T04:25:17Z","timestamp":1717302317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805118302166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":33,"alternative-id":["S0969805118302166"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.08.005","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the feasibility of intranasal radiotracer administration for in brain PET imaging","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}